| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514380000 | Chalcogen or nitrogen bonded directly to ring carbon of the oxazole ring | 40 |
| 20080269304 | Parakeratosis inhibitor, pore-shrinking agent and skin preparation for external use - It is intended to provide a substance having an effect of shrinking pores by analyzing the mechanism of making pores perceptible and compositions such as a skin preparation for external use which exerts the above effect to thereby make pores imperceptible. As means for solving these problems, there are provided a parakeratosis inhibitor and a pore-shrinking agent comprising an antagonist to an excitatory cell receptor, for example, a glutamate receptor such as N-methyl-D-aspartic acid receptor or an ATP receptor such as P2X receptor, or an agonist to an inhibitory cell receptor such as a γ-aminobutyrate receptor such as bicuculline-sensitive receptor having the Cl-channel therein or glycine receptor, as well as a skin preparation for external use aiming at inhibiting parakeratosis and a skin preparation for external use aiming at shrinking pores each containing such an antagonist to an excitatory cell receptor or an agonist to an inhibitory cell receptor as described above. Owing to the effects of inhibiting parakeratosis and shrinking pores, the skin can be maintained in a healthy state without perceptible pores. | 10-30-2008 |
| 20090118341 | Method for treatment of chronic neuropathic pain - Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and/or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors. | 05-07-2009 |
| 20090131491 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I - Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. | 05-21-2009 |
| 20090215842 | Method of Treating Schizophrenia Prodrome - The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixtures thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient. | 08-27-2009 |
| 20100048653 | NEUROPROTECTIVE MODULATION OF NMDA RECEPTOR SUBTYPE ACTIVITIES - In various aspects, the invention provides methods and compositions for modulating NMDA receptor subtype activity, to enhance NR2A-containing NMDA receptor activity relative to NR2B-containing NMDA receptor activity, so as to effect a neuroprotective reduction in excitotoxic NMDA receptor activity | 02-25-2010 |
| 20100056589 | PLANT DISEASE DAMAGE CONTROL COMPOSITION AND PLANT DISEASE DAMAGE PREVENTION AND CONTROL METHOD - The invention provides a plant disease control composition including active ingredients of (RS)—N-[2-(1,3-dimethylbutyl)thiophene-3-yl]-1-methyl-3-trifluoromethyl-1H-pyrazole-4-carboxamide (common name: penthiopyrad) and at least one fungicidal compound other than penthiopyrad, and a plant disease prevention method wherein such a compound is applied to plant seeds or soil. According to the invention, a composition and a prevention method are provided which demonstrate a prevention effect against plural types of disease pathogenic microbes, and also demonstrate a preventing effect to currently emerging resistant pathogenic microbes, when applied to plant seed or soil. | 03-04-2010 |
| 20100152257 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 06-17-2010 |
| 20100173962 | HETEROARYL (SUBSTITUTED)ALKYL N-SUBSTITUTED SULFOXIMINES AS INSECTICIDES - N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects. | 07-08-2010 |
| 20100204290 | PROCEDURE FOR OPERATING A PARTICLE FILTER ARRANGED IN AN EXHAUST FUME AREA OF A BRENNKRAFTMASCHINE AND DEVICE TO EXECUTE THE PROCEDURE - A method of increasing the survival of animals and aquatic species susceptible to birnavirus infection by treating them before, during and/or after bimavirus exposure, with a chemical compound capable of inhibiting viral replication. A method of treating aquatic species to increase their survival in the presence of a virus, particularly an aquatic bimavirus, and to increase the yield of farmed fish susceptible to viral infection. The present invention provides methods for increasing survival of virally-exposed aquatic animals by administering therapeutically effective amounts of isoxazol compounds to aquatic animals susceptible to bimavirus infection and/or IPNV infection, particularly in fish such as salmonoid species, which are easily exposed to IPNV. The present invention also provides methods for increasing survival of virally-exposed animals by administering therapeutically effective amounts of isoxazol compounds to farmed animals susceptible to bimavirus infection and/or IBDV infection, particularly in poultry such as chickens, which are exposed to IBDV. | 08-12-2010 |
| 20100204291 | Method for Facilitating Extinction Training Using D-Cycloserine - Methods are disclosed for improving treatment of various medical conditions via administration of D-cycloserine to facilitate learning. Specifically, by administering D-cycloserine on a post-training pre-sleep basis, subsequent to extinction training during the day, the methods can improve upon the known ability of D-cycloserine to facilitate extinction learning. | 08-12-2010 |
| 20100280086 | SUBSTITUTED THIOPHENES - Disclosed herein are substituted pyrimidine-based endothelin modulators of Formula I, processes of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof. | 11-04-2010 |
| 20100298392 | Isoindoline Derivatives For The Treatment Of Arrhythmias - There is provided compounds of formula I, wherein R | 11-25-2010 |
| 20100298393 | Modulation of Growth Hormone, DHEA, and Cortisol with Positive Modulators of AMPA Type Glutamate Receptors - Methods for modulating the endocrine system of a mammal are provided. In the subject methods, a positive allosteric modulator of AMPA receptors of the hypothalamus are administered to the host. The subject methods find use in applications where it is desired to increase the baseline circulatory level of a growth hormone in a mammalian host. The subject methods also find use in applications where it is desired to increase the circulatory level of DHEA in a mammalian host. Finally, another subject method also finds use in applications where it is desired to decrease the circulatory level of cortisol in a mammalian host. | 11-25-2010 |
| 20110021584 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for treating hypoglycemia. The methods are useful for treating diabetes mellitus and screening drug candidates for potential efficacy. | 01-27-2011 |
| 20110039903 | Acute Pharmacologic Augmentation of Psychotherapy with Enhancers of Learning or Conditioning - Methods for treating an individual with a psychiatric disorder with a pharmacologic agent that enhances learning or conditioning in combination with a session of psychotherapy are provided. These methods of the invention encompass a variety of methods of psychotherapy, including exposure-based psychotherapy, cognitive psychotherapy, and psychodynamically oriented psychotherapy, and psychiatric disorders including fear and anxiety disorders, addictive disorders including substance-abuse disorders, and mood disorders. The pharmacologic agents used for the methods of the present invention are ones that generally enhance learning or conditioning, including those that increase the level of acetylcholine in the brain, and those that enhance N-methyl-D-aspartate (NMDA) receptor transmission in the brain. | 02-17-2011 |
| 20110082181 | Compounds as Lysophosphatidic Acid Receptor Antagonists - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 04-07-2011 |
| 20110124695 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I: | 05-26-2011 |
| 20110124696 | Sulfone Compounds Which Modulate The CB2 Receptor - Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain. | 05-26-2011 |
| 20110160260 | Method of Treating a Neurodegenerative Disorder - The present invention provides a method of treating a neurodegenerative disorder in a patient, comprising administration to the patient a therapeutically effective amount of D-cycloserine and its derivatives. | 06-30-2011 |
| 20110196005 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 08-11-2011 |
| 20110207788 | 5-Ring Heteroaromatic compounds and their use as binding partners for 5-ht5 receptors - The invention relates to 5-ring heteroaromatic compounds of general formula (I), their use for the treatment and/or prevention of diseases, and medicaments containing same. | 08-25-2011 |
| 20110301211 | ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS - Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases. | 12-08-2011 |
| 20120202862 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I; | 08-09-2012 |
| 20120225916 | Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine - The invention describes methods and compositions for alleviating medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical compound that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction, wherein D-cycloserine is the pharmaceutical compound that enhances learning. Representative afflictions include pain, mood disorders, anxiety disorders including performance anxiety, insomnia, female sexual dysfunction, chronic fatigue, autism spectrum disorders, fibromyalgia, and attention deficit-hyperactivity disorder. | 09-06-2012 |
| 20130005783 | Prevention And Treatment Of Diseases Caused By Elevated Levels Of Deoxy-Sphingolipids - Substances and methods of use of substances capable of inhibiting serine-palmitoyltransferase (SPT) and/or capable of competing with L-alanine and glycine, including in the reaction catalysed by SPT, including L-serine and D-serine and other compounds, to suppress cytotoxic sphingolipid metabolites, in particular deoxy-sphingolipids. The substances and methods can be used to prevent and treat disease caused by or associated with elevated levels of deoxy-sphingolipids, namely, diabetes (type 1 and type 2 diabetes), particularly diabetic neuropathy, neurodegenerative diseases such as hereditary and sensory neuropathy type I (HSAN1), amyotrophic lateral sclerosis (ALS), Alzheimer disease, other neurological disorders (e.g. depressive disorders, schizophrenia), medication-induced neuriopathies (e.g. induced by treatment with cytostatics like paclitaxel, cis-platin compounds etc.) and other metabolic disorders such as glycogen storage disease type 1a and asthma. | 01-03-2013 |
| 20130041000 | NOVEL AZOLE COMPOUND - Azole compounds represented by formula I: | 02-14-2013 |
| 20130096168 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I; | 04-18-2013 |
| 20130197045 | SITAXENTAN DERIVATIVE - A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect: | 08-01-2013 |
| 20130217738 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for treating hypoglycemia. The methods are useful for treating diabetes mellitus and screening drug candidates for potential efficacy. | 08-22-2013 |
| 20130253023 | POLYCYCLIC LPA1 ANTAGONIST AND USES THEREOF - Described herein is the LPA1 antagonist 1-{4′-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-bi-phenyl-4-yl}-cyclopropanecarboxylic acid (Compound 1), or pharmaceutically acceptable salts thereof. Also described are methods of preparing the LPA1 antagonist, or pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions suitable for administration to a mammal that include the LPA1 antagonist, or pharmaceutically acceptable salt thereof, and methods of using such pharmaceutical compositions for treating LPA-dependent or LPA-mediated diseases or conditions. | 09-26-2013 |
| 20140024690 | Isoxazole Derivatives Useful As Antibacterial Agents - The present invention is directed to a new class of hydroxamic acid derivatives, their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections. | 01-23-2014 |
| 20140088165 | Substituted carbamoylmethylamino acetic acid derivatives as novel NEP inhibitors - The present invention provides a compound of formula I; | 03-27-2014 |
| 20140121254 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MOVEMENT DISORDERS - The invention provides a pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier. | 05-01-2014 |
| 20140142149 | ORAL FORMULATIONS OF DIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR AGONISTS TO TREAT ELEVATED BLOOD PRESSURE AND DIABETIC NEPHROPATHY - Methods of administering and pharmaceutical compositions of a biphenyl sulfonamide compound which is a dual angiotensin and endothelin receptor antagonist are disclosed for treating diseases. | 05-22-2014 |
| 20140142150 | TREATING NEUROPSYCHIATRIC DISORDERS - The specification provides methods of treating a subject suffering from a neuropsychiatric disorder and methods of determining whether a subject is suffering from or at risk for developing a neuropsychiatric disorder or likely to respond to a specified treatment method. | 05-22-2014 |
| 20140187597 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MOVEMENT DISORDERS - A pharmaceutical composition, medical food, dietary supplement or micronutrient for the treatment of a movement disorder comprising an NMDAR agonist or partial agonist as active ingredient therein in combination with a pharmaceutically acceptable carrier. | 07-03-2014 |
| 20140213621 | METHOD FOR TREATMENT OF CHRONIC NEUROPATHIC PAIN - Chronic pain is treated in an individual suffering from chronic pain by administering to the individual an amount of a therapeutic containing a glycine receptor agonist such as D-cycloserine or a GlyT-1 glycine transporter antagonist such as sarcosine in an amount effective to treat the chronic pain. The therapeutic may also contain a secondary analgesic such as opiates, NSAIDs or cox-2 inhibitors. The analgesic can be formulated in a pharmaceutical composition in the form of an injectable solution that contains at least two different analgesics, at least one of the analgesics of which is a glycine receptor agonist or a GlyT-1 glycine transporter antagonist. Suitable pharmaceutical compositions contain D-cycloserine and/or sarcosine, optionally in combination with opiates, NSAIDs or cox-2 inhibitors. | 07-31-2014 |
| 20150105436 | Methods and Assays for Detecting and Treating Hypoglycemia - Methods for regulating glucagon release and of treating hypoglycemia, and for screening drug candidates for heating hypoglycemia. The methods are useful for treating diabetes melititus and screening drug candidates for potential efficacy. | 04-16-2015 |
| 20160083372 | NEPRILYSIN INHIBITORS - In one aspect, the invention relates to compounds having the formula: | 03-24-2016 |
| 20190144380 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | 05-16-2019 |
